Evidence map›Paper›PMID 40319068›Full record

ArticleCell death & disease2025

Therapy-induced senescence of glioblastoma cells is determined by the p21

Christian Schwarzenbach, Justus Rinke, Juliana B Vilar, Jason Sallbach, Larissa Tatsch, Ariane Schmidt, Anna Schöneis, Birgit Rasenberger, Bernd Kaina, Maja T Tomicic and 1 more

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Sanguinarine chloride exerts its antitumor effects on enzalutamide-resistant prostate cancer by inhibiting cell proliferation and promoting senescence via targeting AR signaling.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christian SchwarzenbachDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.ORCID http://orcid.org/0000-0002-9323-0053
Justus RinkeDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Juliana B VilarDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.ORCID http://orcid.org/0000-0002-7213-568X
Jason SallbachDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Larissa TatschDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Ariane SchmidtDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Anna SchöneisDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Birgit RasenbergerDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Bernd KainaDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.ORCID http://orcid.org/0000-0002-8217-0809
Maja T TomicicDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. tomicic@uni-mainz.de.ORCID http://orcid.org/0000-0001-9289-4168
Markus ChristmannDepartment of Toxicology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. mchristm@uni-mainz.de.ORCID http://orcid.org/0000-0002-9672-231X

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 393547839 TP05Deutsche Forschungsgemeinschaft (German Research Foundation) 470145176Deutsche Forschungsgemeinschaft (German Research Foundation) 508828494Wilhelm Sander-Stiftung (Wilhelm Sander Foundation) 2019.154.1
6 · The paper itself

Abstract

Therapy-induced senescence (TIS) is a major challenge in cancer therapy as senescent cancer cells provoke local and systemic inflammation and might be the cause of recurrences. Elucidation of pathways leading to TIS is of utmost importance for establishing strategies to counteract this. Previously we have shown that temozolomide (TMZ), an alkylating drug used forefront in glioma therapy, causes majorly cellular senescence, which is triggered by the primary damage O

Indexed as

CDC2 Protein KinaseCellular SenescenceCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p21GlioblastomaRepressor ProteinsCell Line, TumorForkhead Box Protein M1G2 Phase Cell Cycle CheckpointsHumansSignal TransductionTemozolomideCDC2 Protein KinaseCDK1 protein, humanCDK2 protein, humanCDKN1A protein, humanCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p21Forkhead Box Protein M1Repressor ProteinsTemozolomide

Identifiers

PMID40319068
PMCPMC12049523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.